Imexpharm

Imexpharm FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Imexpharm (IMP.VN) as of Oct 26, 2026 is 7.82 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 37.24 % — a change of -79.01% (lower).

FCF Conversion

7.82 %

YoY

-79.01%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Imexpharm is 2025 7.82 % . FCF Conversion Rate (FCF/EBITDA) of Imexpharm was 2024 37.24 % . It decreases by -79.01% lower compared to the previous year.

The Imexpharm FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-115.00 VND
Jan 1, 2019
-39.74 VND
Jan 1, 2020
-7.88 VND
Jan 1, 2021
96.26 VND
Jan 1, 2022
124.92 VND
Jan 1, 2023
-34.57 VND
Jan 1, 2024
37.24 VND
Jan 1, 2025
7.82 VND
The Imexpharm FCF Conversion history
YEARFCF ConversionYoY
7.82 %-79.01%
37.24 %-207.72%
-34.57 %-127.68%
124.92 %+29.77%
96.26 %-1,321.06%
-7.88 %-80.16%
-39.74 %-65.44%
-115.00 %-32.99%
-171.62 %+684.49%
-21.88 %-43.52%
-38.73 %+109.74%
-18.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

FCF Conversion Rate (FCF/EBITDA) of Imexpharm is 7.82 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Imexpharm changed from 37.24 % to 7.82 %, representing a -79.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Imexpharm since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Imexpharm with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Imexpharm

All Key Metrics — Imexpharm